Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study will be a randomized, placebo controlled, double blind study to measure the safety
and efficacy of a new, injectable asthma medication, omalizumab, in a group of minority with
moderate to severe asthma who are not adequately controlled with use of inhaled or oral
steroids. Primary endpont will be change in asthma symptom utility index. Secondary endpoints
will be changes in asthma Quality of life, asthma exacerbation rate, and lung function over
the 12 week treatment period.